CLINICAL IMPACT - Ask the experts: Tumor microenvironment in breast cancer
Dr. Asselah and Dr. Park discuss the impact of microenvironment interactions on tumor growth, treatment resistance, and potential therapeutic strategies with a focus on bridging basic to clinical research.
Q1: In which patient profiles would you consider standard of care T-DXd for in the 2L HER2+ mBC setting? And is there a patient profile you would not consider it?
Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial